Question explored with the scientific record
Conversation so far
- 1 Do statins reduce strokes?
- 2 What benefits do statins show for people without heart disease (primary prevention)?
- 3 What about ezitimibe for cardiovascular disease and stroke prevention
- 4 What are the main safety risks of ezetimibe+statin (e.g., cancer)?
- 5 What about ezetimibe without statin? Is it an effective therapy?
- 6 How much LDL lowering and heart-risk reduction does ezetimibe monotherapy achieve?
- 7 Is ezetimibe alone effective in lowering apoB?
- 8 What is the best way to lower apoB dramatically without a statin
- 9 How much apoB can ezetimibe lower compared with PCSK9 inhibitors?
Answered on this page ↓
How much apoB can ezetimibe lower compared with PCSK9 inhibitors?
Ezetimibe alone lowers apoB by about 15–20%, while PCSK9 inhibitors cut it by roughly 50–60% — the difference is roughly threefold.
The evidence from this retrieval confirms that gap. In a small pre-post study of 20 men, ezetimibe 10 mg daily for four weeks reduced fasting apoB from 118 to 94.5 mg/dL, a drop of about 20% [1]. A separate trial in type 2 diabetes found ezetimibe alone lowered LDL-C by 14.6% and small-dense LDL apoB by 20% [3]. Those numbers are consistent: ezetimibe's effect on apoB is modest.
PCSK9 inhibitors are in a different class. A pooled analysis of evolocumab trials in mixed hyperlipidemia showed LDL-C reductions of roughly 65–67% compared with placebo, and about 39–42% compared with ezetimibe [2]. The LAPLACE-TIMI 57 trial found evolocumab 140 mg every two weeks cut LDL-C by 66% on top of statin therapy [4]. ApoB reductions follow the same pattern [2][4]. In a case report, a woman on evolocumab plus bempedoic acid saw her apoB drop from 129 to 79 mg/dL — a 39% reduction — but that was combination therapy, not PCSK9 alone [5].
| Drug class | Typical apoB/LDL-C reduction | Source |
|---|---|---|
| Ezetimibe alone | ~15–20% apoB, ~15% LDL-C | [1][3] |
| PCSK9 inhibitor alone | ~50–60% LDL-C, apoB follows | [2][4] |
| PCSK9i + ezetimibe | ~39–42% more than ezetimibe alone | [2] |
The caveat: nearly all this evidence comes from manufacturer-funded trials using surrogate lab endpoints, not hard clinical outcomes like heart attacks or deaths [2][4]. The lab reductions are real, but whether they translate to proportional risk reduction in every patient is less certain.
My call: PCSK9 inhibitors lower apoB roughly three times more than ezetimibe alone. Confidence: high for the lab comparison, moderate for long-term clinical benefit.
Sources used 5
-
The effect of ezetimibe on lipid and glucose metabolism after a fat and glucose load
In a pre-post study of 20 overweight/obese Japanese men, four weeks of ezetimibe (10 mg daily) improved postprandial lipid and glucose metabolism after a fat-and-glucose load, reducing triglycerides, apoB-48, LDL-cholesterol, apolipoprotein B, fasting glucose, and postprandial g…
DOI: 10.1016/j.jjcc.2012.07.010 -
Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
A post-hoc pooled analysis of multiple evolocumab trials shows substantial LDL-C reduction in patients with mixed hyperlipidemia (elevated triglycerides) that is similar to those without elevated triglycerides, with concurrent improvements in non-HDL-C and ApoB and overall good …
DOI: 10.1007/s10557-016-6666-1 -
Ezetimibe alone and in combination lowers the concentration of small, dense low-density lipoproteins in type 2 diabetes mellitus
A multicenter, randomized, open-label 6-week trial in type 2 diabetes showed that ezetimibe alone and in combination with simvastatin lowers the concentration of atherogenic small, dense LDL (sdLDL) particles, with combination therapy yielding substantial reductions in sdLDL and…
DOI: 10.1016/j.atherosclerosis.2011.10.043 -
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study
In statin-treated adults with hypercholesterolaemia, a human monoclonal antibody against PCSK9 (AMG 145) produced dose-dependent, large reductions in LDL-C over 12 weeks with good tolerability in a multicentre randomized trial, supporting PCSK9 inhibition as a new lipid-manageme…
DOI: 10.1016/S0140-6736(12)61770-X -
A Call for Use of Lipid Fractionation Studies in Patients With Abnormal Standard Lipid Profiles
A case report demonstrating the use of ion mobility lipid fractionation to guide intensive lipid-lowering therapy in a patient with abnormal standard lipid profiles, showing marked reductions in small dense LDL, ApoB, LDL particle number and LDL-C with PCSK9 inhibition and add-o…
DOI: 10.1210/jcemcr/luaf117